NRAS Mutation Detection by Pyrosequencing
2003123
Ordering Recommendation
Predicts response to anti-EGFR and MAPK pathway therapies in a variety of malignancies (eg, melanoma and colorectal cancer).
Mnemonic
NRAS
Methodology
Polymerase Chain Reaction/Pyrosequencing
Performed
Sun-Sat
Reported
7-12 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
- Patient Preparation
- Collect
- Tumor tissue. Also acceptable: DNA extracted by CLIA certified lab with corresponding client-circled H&E slide.
- Specimen Preparation
- Tumor Tissue: Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block or 5 unstained 5 micron slides. (Min: 3 slides). Transport block and/or slide(s) in a tissue transport kit (ARUP Supply # 47808) available online through eSupply using ARUP Connect™or contact ARUP Client Services at (800) 522-2787.
Extracted DNA: Transport 40 uL DNA with at least 50 ng/uL concentration. (Min: 40 uL) Transport DNA in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. - Storage/Transport Temperature
- Room temperature. Ship in cooled container during summer months.
Extracted DNA: Refrigerated. - Unacceptable Conditions
- Less than 25 percent tumor. DNA extracted by a non-CLIA lab. DNA extracted without a corresponding circled H&E slide. Specimens fixed/processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). Decalcified specimens.
- Remarks
- Include surgical pathology report.
- Stability
- Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Extracted DNA: Ambient: 1 month; Refrigerated: Indefinitely; Frozen: Indefinitely
Reference Interval
Interpretive Data
Refer to report.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Note
This assay detects mutations in codons 12, 13, and 61.
Hotline History
View Hotline History
CPT Code(s)
88381; 81311
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2002148 | Block ID | 57723-9 |
| 2003124 | NRAS Mutation Detection, Pyrosequencing | 21719-0 |
Aliases
- Anti-EGFR therapy resistance
- Codon 12,13
- Codon 61
- N-RAS
- RAS Mutation Analysis, Thyroid Cancer